| 重组人促血小板生成素在多发性骨髓瘤患者自体外周血干细胞移植中的临床应用 |
| |
| 引用本文： | 杨光忠,高文,王国蓉,李燕郴,吴垠,刘爱军,冷芸,陈文明. 重组人促血小板生成素在多发性骨髓瘤患者自体外周血干细胞移植中的临床应用[J]. 中国癌症防治杂志, 2021, 13(4): 380-384. DOI: 10.3969/j.issn.1674-5671.2021.04.09 |
| |
| 作者姓名： | 杨光忠 高文 王国蓉 李燕郴 吴垠 刘爱军 冷芸 陈文明 |
| |
| 作者单位： | 华中科技大学同济医学院附属同济医院血液内科 |
| |
| 基金项目： | 国家自然科学基金项目（82070211） |
| |
| 摘 要： | 目的 探讨重组人促血小板生成素(recombinant human thrombopoietin,rhTPO)在多发性骨髓瘤(multiple myeloma,MM)患者自体外周血干细胞移植(autologous peripheral blood stem cell transplantation,APBSCT)中的临...
|
| 关 键 词： | 多发性骨髓瘤 促血小板生成素 自体 移植 |
Clinical application of recombinant human thrombopoietin in patients with multiple myeloma duringautologous peripheral blood stem cell transplantation |
| |
| YANG Guangzhong,GAO Wen,WANG Guorong,Li Yanchen,WU Yin,LIU Aijun,LENG Yun,CHEN Wenming. Clinical application of recombinant human thrombopoietin in patients with multiple myeloma duringautologous peripheral blood stem cell transplantation[J]. Journal of Chinese Medical Abstracts·Oncology, 2021, 13(4): 380-384. DOI: 10.3969/j.issn.1674-5671.2021.04.09 |
| |
| Authors: | YANG Guangzhong GAO Wen WANG Guorong Li Yanchen WU Yin LIU Aijun LENG Yun CHEN Wenming |
| |
| Abstract: | Objective To analyze the clinical characteristics and efficacy of chimeric antigen receptors-modified T cells (CAR-T) based therapy in the treatment of patients with refractory/relapsed B-cell tumor. Methods The data of 2 patients with B-cell tumor who developed a secondary tumor after CD19 and CD22 CAR-T therapy were retrospectively analyzed, and the related literature was reviewed. Results One case was diagnosed as follicular lymphoma and had a progression-free survival of 28 months after treatment with CD19 and CD22 CAR-T therapy, followed by secondary adenocarcinoma; the other case was diagnosed as acute B-lymphoblastic leukemia and had a progression-free survival of 14 months after CD19 CAR-T therapy, followed by secondary acute myeloid leukemia. Conclusions A great breakthrough is made in CAR-T therapy for the treatment of B-cell tumor patients. However, the therapy still has long-term adverse reactions in clinical application, such as the secondary tumor, which needs a long-term follow-up and summary in clinical practice. |
| |
| Keywords: | CAR-T therapy B-cell tumor Secondary tumor Long-term adverse reactions |
| 本文献已被 维普 等数据库收录！ |
| 点击此处可从《中国癌症防治杂志》浏览原始摘要信息 |
|
点击此处可从《中国癌症防治杂志》下载免费的PDF全文 |
|
